The latest research result, the immune score test, can now more accurately define the disease progression of colon cancer patients. According to an international study of more than 2,500 patients, immune scores have been shown to be effective in predicting which patients have a high risk of tumor recurrence and can benefit from intensive treatment after surgery.
Ana buƙatar ƙididdige tsananin tsananin ciwon kansar hanji bisa yaɗuwar sa da kuma ƙazamin hanji. Wannan kiyasin ciwon daji da kuma hadarin sake dawowa bayan jiyya zai inganta magani. Shekaru da yawa, an yi imanin cewa amsawar rigakafi na marasa lafiya zai yi tasiri mai amfani akan ciwon daji. Binciken na baya-bayan nan ya nuna cewa mamayewar ciwace-ciwacen daji ta hanyar sel na rigakafi na iya zama alama mai kyau na alkiblar ci gaban cutar kansar launin fata, ta zama kayan aiki mai yuwuwa don gano yawan ƙwayoyin rigakafi tare da mafi yawan bayanai game da ci gaban cutar.
Creationirƙirar wannan gwajin na rigakafi ya dace da aikin asibiti. Yana aiki ta hanyar ƙididdigar yawaitar ƙwayoyin cuta guda biyu a cikin ƙari da gefen mamayewarsu: duka ƙwayoyin T (CD3 +) da ƙwayoyin T masu kisa (cytotoxic CD8 +). Wannan binciken ya kimanta kimar hangen nesa na marasa lafiya da ke da girman sikirin babban hanji, gami da marasa lafiya 2681 daga cibiyoyi daban-daban. Dangane da haɗarin sake dawowa (shekaru 5 bayan tiyata) da kimanta yawan rayuwa, an raba marasa lafiya zuwa ƙungiyoyi uku (manya, matsakaita da ƙananan) matakan rigakafi don hango hangen nesa game da aikin hangen nesa. Sakamakon ya nuna cewa marasa lafiyar da ke dauke da yawan garkuwar jiki suna gabatar da mafi kasadar kasadar sake dawowa da kuma tsawon rayuwa.
Of the 700 patients, only 8% of patients with high scores relapsed after 5 years. However, the relapse rate of patients with middle and low scores increased significantly, reaching 19% and 32%, respectively. These findings indicate that the immune score provides an accurate and reliable assessment of the risk of colon cancer recurrence. Use the risk of recurrence to improve individual patient treatment strategies, especially changes in chemotherapy regimens. In view of the highly positive results of colon cancer, immunoscore tests for other cancers are under way, which will revolutionize the treatment of cancer patients.
